The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses the clinical outcomes for patients with myelofibrosis after the immediate transition from ruxolitinib to momelotinib. The SIMPLIFY (NCT01969838 and NCT02101268) and MOMENTUM (NCT04173494) trials had already shown this transition was safe, but with the recent approval of momelotinib by the FDA, real-world data has been accumulated. This has shown that momelotinib is safe, effective, and can improve the symptoms of patients with anemia. The ruxolitinib to momelotinib transition is being further validated in this real-world data. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
